Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C3H7NO2 |
| Molecular Weight | 89.0932 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](N)C(O)=O
InChI
InChIKey=QNAYBMKLOCPYGJ-REOHCLBHSA-N
InChI=1S/C3H7NO2/c1-2(4)3(5)6/h2H,4H2,1H3,(H,5,6)/t2-/m0/s1
| Molecular Formula | C3H7NO2 |
| Molecular Weight | 89.0932 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: Nelson, David L.; Cox, Michael M. (2005), Principles of Biochemistry (4th ed.), New York: W. H. Freeman.Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00160
Sources: Nelson, David L.; Cox, Michael M. (2005), Principles of Biochemistry (4th ed.), New York: W. H. Freeman.
Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00160
Alanine is a non-essential aminoacid encoded by GCU, GCC, GCA, and GCG codons. Besides being a building block of proteins, alanine plays a key role in glucose-alanine cycle. Alanine is medically used as a dietary supplement for conditions such as fructose intolerance, muscle atrophy, low birth weight.
Originator
Sources: http://www.aminoacidsguide.com/Ala.html
Curator's Comment: Alanine was first synthesized in 1850 by Adolph Strecker
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL5929 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6016324 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | FREAMINE III 10% Approved UseParenteral nutrition with 8.5% FreAmine® III (Amino Acid Injection) with Electrolytes is
indicated to prevent nitrogen loss or treat negative nitrogen balance in adults and pediatric
patients, where (1) the alimentary tract, by the oral, gastrostomy, or jejunostomy route, cannot or
should not be used, or adequate protein intake is not feasible by these routes; (2) gastrointestinal
absorption of protein is impaired; or (3) protein requirements are substantially increased as with
extensive burns. Dosage, route of administration, and concomitant infusion of non-protein
calories are dependent on various factors, such as nutritional metabolic status of the patient, anticipated duration of parenteral nutritional support, and vein tolerance Launch Date1971 |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Reaction mechanism of alanine racemase from Bacillus stearothermophilus: x-ray crystallographic studies of the enzyme bound with N-(5'-phosphopyridoxyl)alanine. | 2002-05-24 |
|
| Structural characterization of the M* partly folded intermediate of wild type and P138A aspartate aminotransferase from Escherichia coli. | 2002-05-17 |
|
| 3-Hydroxykynurenine transaminase identity with alanine glyoxylate transaminase. A probable detoxification protein in Aedes aegypti. | 2002-05-03 |
|
| Dye-linked D-proline dehydrogenase from hyperthermophilic archaeon Pyrobaculum islandicum is a novel FAD-dependent amino acid dehydrogenase. | 2002-04-12 |
|
| Physiological roles of free D- and L-alanine in the crayfish Procambarus clarkii with special reference to osmotic and anoxic stress responses. | 2002-04 |
|
| A Y2 receptor mimetic aptamer directed against neuropeptide Y. | 2002-03-29 |
|
| Mechanisms of the protective effect of L-alanine to D-galactosamine-induced hepatocellular injury: comparative studies of L-alanine and pyruvate. | 2002-03-08 |
|
| Glycine oxidase from Bacillus subtilis. Characterization of a new flavoprotein. | 2002-03-01 |
|
| Nepenthes insignis uses a C2-portion of the carbon skeleton of L-alanine acquired via its carnivorous organs, to build up the allelochemical plumbagin. | 2002-03 |
|
| The unique ribbon morphology of the major ampullate silk of spiders from the genus Loxosceles (recluse spiders). | 2002-02-28 |
|
| Transport of D-serine via the amino acid transporter ATB(0,+) expressed in the colon. | 2002-02-22 |
|
| Mutations in the carboxyl-terminal domain of phospholipase C-beta 1 delineate the dimer interface and a potential Galphaq interaction site. | 2002-02-08 |
|
| Analysis of the E. coli NifS CsdB protein at 2.0 A reveals the structural basis for perselenide and persulfide intermediate formation. | 2002-02-01 |
|
| Antitumour and toxic effects on Wistar rats of two new platinum complexes. | 2002-02 |
|
| Preparation of optically active allothreonine via optical resolution by replacing crystallization. | 2002-02 |
|
| EPR dosimetric properties of 2-methylalanine: EPR, ENDOR and FT-EPR investigations. | 2002-02 |
|
| In vitro hepatotoxicity of alachlor and its by-products. | 2002-01-25 |
|
| Oligomeric beta(beta)(alpha) miniprotein motifs: pivotal role of single hinge residue in determining the oligomeric state. | 2002-01-23 |
|
| Glycine and alanine dehydrogenase activities are catalyzed by the same protein in Mycobacterium smegmatis: upregulation of both activities under microaerophilic adaptation. | 2002-01 |
|
| Formation of D-alanyl-lipoteichoic acid is required for adhesion and virulence of Listeria monocytogenes. | 2002-01 |
|
| Highly selective molecularly imprinted overoxidized polypyrrole colloids: one-step preparation technique. | 2002-01 |
|
| The effect of Nigella sativa oil against the liver damage induced by Schistosoma mansoni infection in mice. | 2002-01 |
|
| Potential energy surfaces for the gas-phase interaction between alpha-alanine and alkali metal Ions (Li+, Na+, K+). A density functional study. | 2001-12-03 |
|
| Enantioseparation of chiral amino acids as the N(O,S)-ethoxycarbonylated diastereomeric esters by achiral dual-capillary column gas chromatography. | 2001-12 |
|
| Isolation of Bacillus subtilis (chungkookjang), a poly-gamma-glutamate producer with high genetic competence. | 2001-12 |
|
| Antifungal alkyl amino alcohols from the tropical marine sponge Haliclona n. sp. | 2001-12 |
|
| Relationship between hepatitis C virus infection and schistosomal liver disease: not simply an additive effect. | 2001-11 |
|
| Comparison of vaginal aminopeptidase enzymatic activities in various animals and in humans. | 2001-11 |
|
| pH and kinetic isotope effects in d-amino acid oxidase catalysis. | 2001-11 |
|
| Spider silk fibre extrusion: combined wide- and small-angle X-ray microdiffraction experiments. | 2001-10-22 |
|
| Glutamate 47 in 1-aminocyclopropane-1-carboxylate synthase is a major specificity determinant. | 2001-10-16 |
|
| Biochemical characterization of a phosphinate inhibitor of Escherichia coli MurC. | 2001-10-09 |
|
| Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. | 2001-10-01 |
|
| Na+ transport by the neural glutamine transporter ATA1. | 2001-10 |
|
| Lactoferrin-induced reduction of vanB vancomycin resistance in enterococci. | 2001-10 |
|
| Evidence for altered hepatic gluconeogenesis in patients with cirrhosis using in vivo 31-phosphorus magnetic resonance spectroscopy. | 2001-10 |
|
| Possible involvement of amino acid transporters on S-nitroso-cysteine-induced inhibition of arachidonic acid release in PC12 cells. | 2001-09-28 |
|
| Degradation signals in ErbB-2 dictate proteasomal processing and immunogenicity and resist protection by cis glycine-alanine repeat. | 2001-09-15 |
|
| Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. | 2001-09 |
|
| Preparation of and tissue response to DNA-lipid films. | 2001-08 |
|
| Comparison of the omega-transaminases from different microorganisms and application to production of chiral amines. | 2001-08 |
|
| Analysis of the role of bacterial endospore cortex structure in resistance properties and demonstration of its conservation amongst species. | 2001-08 |
|
| Comparison of monomeric and polymeric amino acid based surfactants for chiral separations. | 2001-07-13 |
|
| Structure, activity and evolution of the group I thiolactone peptide quorum-sensing system of Staphylococcus aureus. | 2001-07 |
|
| Safinamide (Newron Pharmaceuticals). | 2001-06 |
|
| Oxygen K-edge X-ray absorption near edge structures (XANES) of sublimated films of amino acids. | 2001-03-01 |
|
| Structure and function of branched chain aminotransferases. | 2001 |
|
| Catalysis of peptide formation by inorganic oxides: high efficiency of alumina under mild conditions on the Earth-like planets. | 2001 |
|
| The genome of Mycobacterium leprae: a minimal mycobacterial gene set. | 2001 |
|
| Water-soluble L-alanine and related oligopeptide conjugates with poly[(R,S)-3-hydroxybutanoic acid] oligomers, synthesis and structural studies by means of electrospray ionization multistage mass spectrometry. | 2001 |
Patents
Sample Use Guides
Alanine is a nutrient, available from animal and vegetarian sources. It could be administered intravenously.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6016324
The extent of transamination was measured by measuring the pyruvate concentration after 10 minutes incubation period with the alanine aminotransferase. The Michaelis constant for alanine was shown to be 28 mM for alanine.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:52:07 GMT 2025
by
admin
on
Mon Mar 31 17:52:07 GMT 2025
|
| Record UNII |
OF5P57N2ZX
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
LOINC |
88018-7
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
32222-2
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
22657-1
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
DSLD |
256 (Number of products:46)
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
44291-3
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
FDA ORPHAN DRUG |
342911
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
47555-8
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
30068-1
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
27326-8
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
15142-3
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
25301-3
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
CFR |
21 CFR 172.320
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
47554-1
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
47553-3
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
47556-6
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
21056-7
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
32221-4
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
47551-7
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
1737-6
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
22724-9
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
1736-8
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
12280-4
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
25843-4
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
CFR |
21 CFR 310.532
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
57994-6
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
21057-5
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
13704-2
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
NDF-RT |
N0000175780
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
1735-0
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
16323-8
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
56671-1
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
25844-2
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
53150-9
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
26795-5
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
DSLD |
2407 (Number of products:622)
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
15137-3
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
50167-6
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
1738-4
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
22698-5
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
47557-4
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
53154-1
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
47552-5
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
27013-2
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
1739-2
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
||
|
LOINC |
20636-7
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
OF5P57N2ZX
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
PRIMARY | |||
|
m1467
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
PRIMARY | Merck Index | ||
|
16449
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
PRIMARY | |||
|
OF5P57N2ZX
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
PRIMARY | |||
|
1012509
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
PRIMARY | |||
|
1801
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
PRIMARY | |||
|
200-273-8
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
PRIMARY | |||
|
56-41-7
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
PRIMARY | |||
|
100000092328
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
PRIMARY | |||
|
DB00160
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
PRIMARY | |||
|
D000409
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
PRIMARY | |||
|
57972
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
PRIMARY | |||
|
C29605
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
PRIMARY | |||
|
4255
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
PRIMARY | |||
|
16977
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
PRIMARY | |||
|
CHEMBL12198
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
PRIMARY | |||
|
DTXSID20873899
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
PRIMARY | |||
|
46217
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
PRIMARY | |||
|
ALANINE
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
PRIMARY | |||
|
5950
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
PRIMARY | |||
|
6161
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
PRIMARY | |||
|
SUB41388
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
PRIMARY | |||
|
SUB05290MIG
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
PRIMARY | |||
|
426
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
PRIMARY | RxNorm | ||
|
206315
Created by
admin on Mon Mar 31 17:52:07 GMT 2025 , Edited by admin on Mon Mar 31 17:52:07 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
LABELED -> NON-LABELED |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|